USPTO Examiner SCHUBERG LAURA J - Art Unit 1631

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19259859HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOFJuly 2025February 2026Abandon710NoNo
18736487CARDIOPULMONARY PROGENITOR EXOSOMES, PREPARATION METHOD AND APPLICATION THEREOFJune 2024December 2025Abandon1831NoNo
18668297Cell Growth Promoter and Application thereofMay 2024October 2025Allow1731YesNo
18629638PLATELET DIAGNOSTIC IMAGING AGENTSApril 2024May 2025Abandon1310NoNo
18627513Fractionating Extracellular Matrix to Modulate Bioactivity and the Host ResponseApril 2024December 2025Abandon2111NoNo
18288332METHOD FOR ENRICHING CELLS OR CELL NUCLEIOctober 2023May 2025Abandon1821YesNo
18359240Use Of Perfusion To Enhance Production Of Fed-batch Cell Culture In BioreactorsJuly 2023April 2025Abandon2101NoNo
18345212BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOFJune 2023March 2025Abandon2101NoNo
18213593METHOD FOR PROMOTING AND IMPROVING PROPERTIES OF ADIPOSE TISSUE, TISSUE AND CELLS OBTAINED BY SAID METHODJune 2023March 2025Abandon2001NoNo
18301864MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN CANINES AND IMPROVED CELL CULTIVATION METHODSApril 2023January 2025Allow2131YesNo
18301856MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN EQUINES AND IMPROVED CELL CULTIVATION METHODSApril 2023January 2025Allow2121YesNo
18194313LACTOBACILLI FOR TREATING CARDIAC DYSFUNCTIONMarch 2023February 2025Abandon2210NoNo
18152249Pharmaceuticals That Promote Functional Regeneration of Damaged TissuesJanuary 2023January 2025Abandon2501NoNo
18061359CANINE BLOOD PLATELET PREPARATIONSDecember 2022February 2026Abandon3901NoNo
17926268CALCINEURIN INHIBITOR TO IMPROVE CD3+CELL SURVIVAL TO THEREBY FACILITATE ENGRAFTMENT OF DONOR CD34+ CELLS IN A RECIPIENTNovember 2022January 2026Abandon3810NoNo
17985641METHODS AND PRODUCTION OF NOVEL PLATELETSNovember 2022February 2026Abandon3901NoNo
17998228ARTIFICIAL ANTIGEN PRESENTING CELL SYSTEM AND USES THEREOFNovember 2022January 2026Abandon3901NoNo
17956347Modulation of Microglia ActivationSeptember 2022March 2025Abandon2920NoNo
17911237Hepatic Stem-Like Cells for the Treatment and/or the Prevention of Liver DisordersSeptember 2022February 2026Abandon4111NoNo
17888245METHOD FOR CULTIVATING STEM CELLS IN VITROAugust 2022May 2025Allow3321YesYes
17859452BONE REPAIR COMPOSITIONSJuly 2022March 2025Abandon3231NoNo
17827077A METHOD FOR TREATING MULTIPLE SCLEROSIS WITH PEPTIDE-LOADED DENDRITIC CELLSMay 2022April 2024Allow2360NoNo
17825366METHOD OF PRODUCING SKIN-DERIVED PRECURSOR CELLSMay 2022March 2024Abandon2210NoNo
17756304Method And System For Identifying And Validating Shared Candidate Antigens And Shared Antigen-Specific T Lymphocyte PairsMay 2022October 2025Abandon4101NoNo
17662704STEM CELL LINE FOR TREATMENT OF VARIOUS MEDICAL CONDITIONSMay 2022April 2024Abandon2311NoNo
17731295ALTERNATING TANGENTIAL FLOW RAPID HARVESTINGApril 2022October 2024Abandon3021NoNo
17726902REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIESApril 2022December 2024Abandon3141YesYes
17711720QUADRI-POSITIVE STROMAL CELL (QPSC) POPULATION FOR SUPERIOR CELL PROTECTION AND IMMUNOMODULATIONApril 2022May 2025Abandon3821YesNo
17687478THERAPEUTIC MONOCYTES FOR PREVENTION OF SUICIDAL IDEATIONMarch 2022January 2025Abandon3421NoNo
17667434METHODS FOR STORAGE OF STEM CELLSFebruary 2022October 2025Abandon4451NoNo
17579153Use of Adipose-Derived Stem Cells for Glaucoma TreatmentJanuary 2022August 2025Abandon4341YesNo
17622190MODULATION OF T CELL CYTOTOXICITY AND RELATED THERAPYDecember 2021May 2025Abandon4101NoNo
17620565SPHINGOLIPIDS FOR GENERATING REGULATORY CD4+ T CELLSDecember 2021May 2025Abandon4101NoNo
176174953D Bioprinted Skin Tissue ModelDecember 2021August 2025Abandon4401NoNo
17615679BONE MARROW MICROGLIA PROGENITOR CELLS AND USES THEREOFDecember 2021November 2025Allow4711YesNo
17527503METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021January 2024Abandon2610NoNo
17527510METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021November 2023Abandon2410NoNo
17527512METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021November 2023Abandon2410NoNo
17527498METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021December 2023Abandon2510NoNo
17527489METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021November 2023Abandon2410NoNo
17527494METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021November 2023Abandon2410NoNo
17527516METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021November 2023Abandon2410NoNo
17527505METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021May 2024Abandon3010NoNo
17527523METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021December 2025Abandon4951NoNo
17527527METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUENovember 2021February 2026Abandon5150YesNo
17454586PLATELET RICH PLASMA FORMULATIONS AND USE THEREOFNovember 2021April 2024Abandon2911NoNo
17499809METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOFOctober 2021August 2023Abandon2310NoNo
17498683MESENCHYMAL STEM CELLS FOR ORAL INFLAMMATION TREATMENTOctober 2021December 2024Abandon3820NoYes
17497779USES OF MESENCHYMAL STEM CELLSOctober 2021May 2024Abandon3120NoNo
17403202GENERATING VASCULOGENIC CELL POPULATIONSAugust 2021May 2024Allow3311YesNo
17387548COMBINATORIAL CULTURE CONDITION ARRAYS AND USES THEREOFJuly 2021December 2025Abandon5221NoNo
17305483METHODS OF TREATMENT USING PLURIPOTENT HUMAN ADIPOSE ADULT STEM CELLSJuly 2021October 2023Allow2711YesNo
17325693METHOD FOR INDUCING HUMAN CHOLANGIOCYTE DIFFERENTIATIONMay 2021October 2023Abandon2911NoNo
17316854BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOFMay 2021July 2023Abandon2610NoNo
17188735Enzyme GranulesMarch 2021August 2025Abandon5450YesNo
17166487ANTI-FIBRINOLYTIC LOADED PLATELETSFebruary 2021December 2023Abandon3411NoNo
17119511ADHERENT STROMAL CELLS DERIVED FROM PLACENTAS OF MULTIPLE DONORS AND USES THEREOFDecember 2020September 2023Abandon3311NoNo
16972926CELL COMPOSITIONS AND USES THEREOFDecember 2020April 2024Abandon4001NoNo
17104548PLATELET DIAGNOSTIC IMAGING AGENTSNovember 2020July 2024Abandon4421YesNo
17086308FOETAL POLYMIX OF MESENCHYMAL STEM CELLS UNDER HYPOXIC CONDITIONS FOR THE TREATMENT OF CLINICAL DISORDERS AND DISEASESOctober 2020August 2024Abandon4521NoNo
17050734EXTRACELLULAR-MATRIX-CONTAINING COMPOSITION, TEMPORARY SCAFFOLD FOR THREE-DIMENSIONAL TISSUE FORMATION, THREE-DIMENSIONAL TISSUE FORMATION AGENT, AND METHOD FOR RECOVERING CELLS FROM THREE-DIMENSIONAL TISSUEOctober 2020November 2025Abandon6041YesNo
17074912HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOFOctober 2020September 2024Allow4751YesNo
17005674ASSEMBLOID - 3D MIMETIC TISSUE STRUCTURE BASED ON PATIENT- DERIVED MULTIPLE CELL TYPES AND METHOD OF MANUFACTURING THE SAMEAugust 2020March 2025Abandon5551YesNo
17003845BREAST MILK DERIVED PROGENITOR CELLS AND CELL SYSTEMSAugust 2020February 2026Abandon6061YesNo
16976072METHOD FOR ISOLATING AND EXTRACTING ADIPOSE-DERIVED STEM CELLS FROM ADIPOSE TISSUE AND CULTURING SAME WITHOUT USING COLLAGENASE, AND KIT FOR ISOLATING AND EXTRACTING ADIPOSE-DERIVED STEM CELLSAugust 2020March 2024Abandon4301NoNo
16994379MESENCHYMAL STROMAL CELLS FOR TREATING SEPSISAugust 2020December 2023Abandon4021NoNo
16985630METHOD FOR PRODUCING SHEET-SHAPED CELL CULTUREAugust 2020August 2025Abandon6031NoNo
16916425LACTOBACILLI FOR TREATING CARDIAC DYSFUNCTIONJune 2020April 2023Abandon3310NoNo
16907799Use Of Perfusion To Enhance Production Of Fed-batch Cell Culture In BioreactorsJune 2020January 2024Abandon4321NoNo
16762829PRODUCTION OF CANINE PANCREATIC ISLETS FROM AN IMMATURE PANCREASMay 2020October 2022Abandon2901NoNo
16755650HOLLOW MICROCARRIER FOR SHEAR-FREE CULTURE OF ADHERENT CELLS IN BIOREACTORSApril 2020November 2024Abandon5541NoNo
16844382Fractionating Extracellular Matrix to Modulate Bioactivity and the Host ResponseApril 2020May 2024Abandon5021NoNo
16834178PROTECTION OF THE VASCULAR ENDOTHELIUM FROM IMMUNOLOGICALLY MEDIATED CYTOTOXIC REACTIONS WITH HUMAN CD34-NEGATIVE PROGENITOR CELLSMarch 2020April 2023Abandon3601NoNo
16648050HUMAN IN VITRO ORTHOTOPIC AND METASTATIC MODELS OF CANCERMarch 2020October 2024Abandon5531NoNo
16818622CANINE BLOOD PLATELET PREPARATIONSMarch 2020April 2024Abandon4931NoNo
16642657METHOD FOR PRODUCING A THREE-DIMENSIONAL BIOLOGICAL STRUCTURE AND SAID STRUCTURE THUS OBTAINEDFebruary 2020October 2025Abandon6041YesNo
16799592SEED TRAIN PROCESSES AND USES THEREOFFebruary 2020December 2025Abandon6060YesNo
16630799SURFACE-MODIFIED POLYMER SCAFFOLDS AND USES THEREOFJanuary 2020August 2025Abandon6050NoNo
16738495COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLSJanuary 2020June 2024Abandon5331NoYes
16627156METHOD FOR PRODUCING LAYERED CELL SHEET AND LAYERED CELL SHEET PRODUCED BY THE SAMEDecember 2019February 2023Allow3720YesNo
16625501METHODS OF ISLET CELL CULTUREDecember 2019November 2023Abandon4621NoNo
16708137IMAGING METHODS TO ASSESS THE EFFICACY OF ANTICANCER DRUGS IN VITRO USING SPONTANEOUSLY-FORMING SPHEROIDSDecember 2019October 2023Abandon4621NoNo
16686158OMENTUM BASED SCAFFOLD AND DELIVERY SYSTEMNovember 2019September 2025Allow6061YesNo
16677735Manufacturing Method and Device for Three-Dimensional Engineered TissueNovember 2019January 2023Abandon3921YesNo
16589220STEM CELLS AS AN INDIVIDUALIZED MATERNAL THERAPY FOR PREVENTION OF PREMATURITYOctober 2019January 2025Abandon6060YesYes
16580954CELL SPHEROIDS CONTAINING CAPILLARY STRUCTURES AND METHODS OF USING SAMESeptember 2019December 2022Abandon3911NoNo
16561721METHOD OF PREPARING MIMICKING ANGIOGENIC CO-SPHEROIDS AND APPLICATION THEREOFSeptember 2019January 2024Allow5241NoNo
16482666COMPOSITIONS AND METHODS COMPRISING CO-CULTURE OF HEPATOCYTESJuly 2019September 2025Abandon6050NoYes
16517010REGULATING STEM CELLSJuly 2019July 2023Abandon4821NoNo
16502232HEPATOCYTE CONSTRUCT AND METHOD FOR PRODUCING THE SAMEJuly 2019December 2024Abandon6051YesNo
16474895Methods for Generating Skeletal Muscle Progenitor CellsJune 2019March 2025Allow6051YesNo
16386247MEDIA AND METHODS FOR EXPANSION OF PLURIPOTENT STEM CELLSApril 2019November 2022Abandon4321YesNo
16382267METHODS FOR ISOLATING AND CULTURING LIVING CELLS USING METHOD OF PERMEABILIZING CELL MEMBRANEApril 2019August 2023Abandon5221YesNo
16377020PHARMACEUTICAL COMPOSITION FOR TREATING DRUG-RESISTANT CANCER COMPRISING EXOSOMES DERIVED FROM DIFFERENTIATING STEM CELLS AS AN ACTIVE INGREDIENTApril 2019May 2023Abandon5050YesNo
16339829COMPOSITION FOR PROMOTING GROWTH OF STEM CELLS COMPRISING PHYTOSPHINGOSINE-1-PHOSPHATE OR DERIVATIVES THEREOF, AND COMPOSITION FOR CULTURING MEDIA OF STEM CELLS COMPRISING SAMEApril 2019November 2024Abandon6051YesNo
16374479METHODS AND COMPOSITIONS FOR PROVISION OF ANGIOGENIC FACTORSApril 2019March 2024Abandon6040NoYes
16358443COMPOSITIONS COMPRISING CARDIOSPHERE-DERIVED CELLSMarch 2019September 2024Abandon6061NoNo
16317456Innervated Artificial Intestine CompositionsJanuary 2019May 2025Abandon6021YesYes
16312062Three-Dimensional Tissue Matrix Scaffold SystemDecember 2018February 2023Abandon5041YesNo
16301494A CO-CULTURE SYSTEM AND METHOD FOR IN VITRO ASSESSMENT OF REVERSE CHOLESTEROL TRANSPORTNovember 2018July 2023Allow5741YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHUBERG, LAURA J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
10
Examiner Affirmed
6
(60.0%)
Examiner Reversed
4
(40.0%)
Reversal Percentile
60.9%
Higher than average

What This Means

With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
27
Allowed After Appeal Filing
7
(25.9%)
Not Allowed After Appeal Filing
20
(74.1%)
Filing Benefit Percentile
37.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SCHUBERG, LAURA J - Prosecution Strategy Guide

Executive Summary

Examiner SCHUBERG, LAURA J works in Art Unit 1631 and has examined 121 patent applications in our dataset. With an allowance rate of 33.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 53 months.

Allowance Patterns

Examiner SCHUBERG, LAURA J's allowance rate of 33.1% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SCHUBERG, LAURA J receive 3.78 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SCHUBERG, LAURA J is 53 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +42.6% benefit to allowance rate for applications examined by SCHUBERG, LAURA J. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 8.3% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 14.8% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 112.0% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.4% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.